Other tissues are not able to recruit the MSCs from the blood because their CSF2 expression remains low after MI.[18] These results support CSF2/CSF2RB as a potential therapeutic target to improve the cardiac homing of intravenously administered MSCs for the treatment of ischemic heart disease. Here, CSF2 is linked to coronary artery disorder.